An elevated serum creatinine in a patient receiving palbociclib. Issue 2 (June 2021)

• Record Type: Journal Article
• Authors: Bonilla, Marco; Bashir, Khawaja Arsalan; Jhaveri, Kenar D
• Is Part Of: Journal of onco-nephrology. Volume 5:Issue 2(2021)
• Page Start: 133
• Page End: 135
• Publication Date: 2021-06
• Subjects: Palbociclib -- CDK4 -- 6 inhibitor -- AKI -- cystatin C -- onconephrology; Nephrology -- Periodicals; Kidneys -- Cancer -- Periodicals; Kidneys -- Tumors -- Periodicals; 616.61
• DOI: 10.1177/23993693211021420
• Languages: English
• ISSNs: 2399-3693

Abstract

Background: Serum Creatinine (SCr) is the most widely used parameter in clinical practice to estimate glomerular filtration rate (GFR). Various drugs have been reported to cause a reversible and transient elevation in SCr without a true reduction in overall kidney function Case Presentation: We describe a case of a 66-year-old-woman with right breast poorly differentiated invasive ductal carcinoma, hormone receptor positive and HER2 negative who received treatment with fulvestrant and palbociclib. The initial dose of Palbociclib was 125 mg orally a day, then reduce to 100 mg orally a day. She presented for evaluation of elevated serum creatinine with decreased eGFR. Upon evaluation an estimated glomerular filtration rate by cystatin C showed kidney function at her baseline for the past year. Conclusion: Palbocicib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Physicians should be aware that patients undergoing therapy with palbociclib require monitoring of kidney function and an increase in serum creatinine from baseline, might represent an inhibitory effect of the secretion of creatinine.